here has been sustained interest in the possibility of using plasma concentrations of antidepressant medications to guide clinical treatment of depression. Early reports suggested linear relationships for plasma concentrations and clinical response for most tertiary
amine tricyclic antidepressants and curvilinear relationships for plasma concentrations and clinical response for secondary amine tricyclic antidepressants (1) (2) (3) (4) (5) . Subsequent studies, however, failed to replicate these reports (6, 7) , and monitoring of tricyclic antidepressant plasma concentrations is now used primarily to assess adequacy of dosage in patients with refractory depression (8) or at risk for adverse reactions (9) .
Fluoxetine and subsequent selective serotonin reuptake inhibitors (SSRIs) have become more widely used than the older tricyclic antidepressants, largely because of their superior tolerability and safety. Although the majority of patients treated, for major depression re-, spond to a daily dose of 20 mg of fluoxetine, others do not. Ideally, a treatment algorithm for nonresponders would provide a means for distinguishing between fluoxetine-treated patients who fail to respond because 20 mg is an inadequate dose and those who fail to respond for other reasons. Determination of plasma fluoxetine concentrations could potentially provide that distincAm J Psychiatry 154:7, July 1997 963 T 
METHOD

Subjects
A total 839 patients (577 women and 262 men), with a mean age of 40 years (SD=11), were enrolled in the study. All patients were initially screened by a research psychiatrist using a semistructured interview modified from the Structured Clini-cal Interview for DSM-III-R (23) , and all subjects satisfied DSM-III-R criteria for major affective disorder (major depression or bipolar disor-der not otherwise specified). A total of 529 patients met DSM-III-R crite-ria for recurrent depressive illness, 432 had chronic depressive illness (of more than 2 years' duration), and 201 had melancholic features. All patients had a minimum score of at least 16 on the 17-item Hamilton Depression Rating Scale (24) at the initial screening visit and at the baseline visit after a 1-week, drug-free period (mean score=21.2, SD=3.8). Symptom severity was rated with the clinical global improvement scale and the 17-item Hamil-ton depression scale (defined as a combination of the following items from the 28-item Hamilton depression scale: items 1-3, 7-11,13-15, and 17 combined with the greater of either items 4-6, 12, and 16 for patients with insomnia, anorexia, and weight loss or items 22-26 for patients with hypersomnia, hy-perphagia, and weight gain).
Before beginning the study, all patients had a complete physical examination and were free of acute medical illness. Patients with stable concurrent medical conditions had to be receiving established medical therapy, and no patient showed evidence of chronic renal, hepatic, endocrine, or neurological disease. None of the patients showed clinically significant laboratory abnormalities. Patients with serum thyroid-stimulating hormone levels greater than 4.5 µIU/ml were excluded from the study. Occasional use of lorazepam or chloral hydrate was permitted for severe insomnia during the first 6 weeks of the study; however, no other psychotropic drugs were permitted. All subjects were medication free for at least 2 weeks before entering the study, and patients who had taken fluoxetine for more than 1 week during the current depressive episode, or who had taken fluoxetine for more than 12 weeks in any previous de-pressive episode, were excluded from the study. The study was ap-proved by the institutional review board at each participating site, and all subjects gave written informed consent to participate.
Procedure
This study was part of a long-term treatment trial to determine the efficacy of fluoxetine in the prevention of depressive relapse. Following a 1-week, drug-free lead-in period, all subjects began treatment with fluoxetine at 20 mg/day. In the initial phase, all subjects were treated with open-label fluoxetine at 20 mg/day for up to 12 weeks. Remitters (patients with a Hamilton depression score of 7 or less for at least 3 consecutive weeks) were then assigned to treatment in a four-arm, double-blind, p rogressively placebo-controlled, 1-year, fixed-dose (20 mg/day) relapse prevention trial. The data reported here are derived from those subjects in the initial, open-label phase of the trial.
Subjects were rated weekly for clinical response for the first 5 weeks, biweekly for the next 4 weeks, and then weekly until week 12 of treatment. Venous blood samples were obtained for fluoxetine plasma concentrations after 8 weeks of treatment. All samples were centrifuged immediately and stored at -20°C until the time of assay. Fluoxetine and norfluoxetine concentrations were determined by using a modification of the gas chromatographic methods previously described (25) .
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Am J Psychiatry 154:7, July 1997 tion. However, data are inconclusive regarding the efficacy of fluoxetine doses greater than 20 mg in nonresponders (10) (11) (12) (13) (14) , as are the results of studies of the relationship between plasma fluoxetine concentrations and clinical response (15) (16) (17) (18) (19) (20) (21) (22) . Similarly, there have been conflicting reports about whether drug-related side effects increase with plasma concentrations (16, 17). Thus, the utility of determining plasma fluoxetine concentrations in patients who do not respond to 20 mg is uncertain, and definitive determination of the relationship between plasma fluoxetine concentrations and symptomatic improvement remains a question of considerable clinical interest. Previous studies may have failed to resolve the issue for reasons related to inadequate size or problems with design. We have therefore reexamined this question (using standardized criteria for entry and evaluation) in a large, prospective study, treating patients with fluoxetine, 20 mg/day. We report here the results of our analysis of the relationship between plasma concentrations of fluoxetine and the active metabolite norfluoxetine and clinical response.
TABLE 3. Plasma Fluoxetine Concentrations for Depressed Patients in Responder and Remitter Groups (N=411)
a a A responder was defined as a patient whose 17-item Hamilton scale score decreased by at least 50% from baseline to week 8. A remitter was defined as a patient whose Hamilton scale score was 7 or less at week 8. b Differences between remitting/nonremitting responders and nonresponders and between remitters and nonresponders/nonremitting responders were not significant (p=0.44-0.99; two-way ANOVA, df=l, 605). Differences between remitting responders and nonresponders were not significant (p=0.61-0.94; two-way ANOVA, df=l, 513).
Statistical Methods
Relationships between clinical efficacy and plasma concentrations among the 8-week, fluoxetine-treated patients were investigated with analyses of variance (ANOYAs), nonlinear modeling, scatterplots, and the Spearman rank correlations. All patients who had both a clinical efficacy and plasma concentration measurement evaluation at 8 weeks were included in the analyses. Patient baseline characteristics of gender, depressive subtype, episode duration, melancholic features, and smoking were examined to determine their effect on plasma concentrations. Clinical efficacy was assessed by using endpoint, absolute, and per-cent change from baseline to endpoinr in Hamilton depression scale scores. Patients were considered responders if their Hamilton depres-sion scores declined by 50% or more. Responders were further subdi-vided into remitters (endpoint Hamilton depression score of 7 or less) and nonremitting responders (Hamilton depression score greater than 7).
All analyses were performed on fluoxetine concentrations, norfluoxetine concentrations, the sum of fluoxetine and norfluoxetine concentrations, and the ratio of fluoxetine to norfluoxetine concentrations. A two-way ANOVA model was fitted to data for each of the concentration variables four times through use of four different classifications of the clinical response variable, i.e., 1) nonresponders. nonremitting responders, and remitters; 2 responders (remitters and nonremitting re sponders) versus nonresponders; 3) remitters versus nonremitters (nonresponders and nonremitting responders); and 4) remitters versus nonresponders. The two-way ANOVA model included terms for the investigative center, clinical response classification, and their interaction. Because of the nonnormal distribution of plasma concentrations, analyses were performed on rank-transformed data t26). In addition, the same four ANOVA models were fitted to data; patients with a placebo response pattern were excluded, (The placebo response pattern has been described by Quitkin et al. [27] .)
The data were fitted to three nonlinear models. The quadratic model, by including the squared plasma concentrations in a standard regression model, tested for a curvilinear relationship in which the greatest improvement would have taken place within a "therapeutic window." The quadratic term was tested while the first-degree term was controlled, through use of type III sums of squares in SAS (28) . The exponential decay model tested for the presence of a negative relationship between clinical outcome and plasma drug concentrations, evaluating whether a therapeutic, "decrement" occurred at high concentrations. The negative exponential model tested for the presence of a positive relationship with improvement that could have occurred at higher plasma concentrations.
Spearman rank correlations between clinical efficacy and plasma concentrations were calculated to assess a more general association without regard to the type of pattern. Scatterplots of clinical efficacy versus plasma concentration were inspected for possible patterns. All tests for main effects were conducted at the two-sided alpha concentration of 0.05, and interaction effects were tested at 0.10.
RESULTS
Efficacy and plasma concentration data were available from 615 patients who received fluoxetine, 20 mg/day, for 8 weeks. Table 1 shows fluoxetine, norfluoxetine, fluoxetine plus norfluoxetine, and fluoxetine/norfluoxetine concentrations for all patients and for patients divided by attributes including the following: gender, unipolar/bipolar illness, chronicity characteristics, melancholic/nonmelancholic illness, and smoker/nonsmoker classification. Men had lower fluoxetine, norfluoxetine, and total fluoxetine plus norfluoxetine concentrations than women, but plasma concentrations were similar tor all other baseline characteristics. Table 2 shows Hamilton depression scores of the same groupings at the end of 8 weeks. On average, Hamilton depression scores decreased by 13 points (SD=7) from baseline. There were no significant effects of baseline characteristics.
Mean plasma concentration measurements for fluoxetine, norfluoxetine, fluoxetine plus norfluoxetine, and fluoxetine/norfluoxetine were similar among nonresponders compared with all responders, remitters compared with all nonremitters, as well as remitters compared with nonresponders (table 3) . Mean plasma drug concentrations were also similar among remitters, nonremitting responders, and nonresponders (table 4) . Repetition of these analyses after exclusion of those patients with a placebo response pattern did not change the results (tables 4 and 5).
Spearman rank correlation coefficients between plasma concentrations and efficacy measures for all patients (table 6) and plasma concentrations and efficacy measures for all patients after exclusion of patients with placebo response patterns (table 7) were not significantly different from zero. Fittings of nonlinear models (exponential decay, negative exponential decay, and quadratic) to Hamilton depression scores were poor for all combinations of plasma concentrations and patients (both with and without placebo pattern responders), providing no evidence of a curvilinear relationship be- A responder was defined as a patient whose 17-item Hamilton scale score decreased by at least 50% from baseline to week 8. A remitter was defined as a patient whose Hamilton scale score was 7 or less at week 8. b Differences between remirring/nonremirring responders and nonresponders and between remitting responders and nonresponders/nonremitting responders were not significant !p=0.51-0.98; two-way ANOVA, df=l, 3521. c Differences between remitting responders and nonresponders were not significant (p=0.60-1.00; two-way ANOVA. df=l, 298). 
DISCUSSION
We report here a prospective study of the relationship between clinical response and plasma concentrations of fluoxetine, norfluoxetine, and total fluoxetine plus norfluoxetine, as well as ratios of fluoxetine to norfluoxetine, in 615 patients with major depression. Remitters, nonremitting responders, and nonresponders showed similar plasma concentrations for fluoxetine, norfluoxetine, fluoxetine plus norfluoxetine, and ratio of fluoxetine to norfluoxetine, and there was no evidence of a relationship between plasma concentrations and clinical response.
There has been considerable interest in determining whether plasma fluoxetine and norfluoxetine concen-
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Am ] Psychiatry 154:7July 1997 3 A responder was defined as a patient whose 17-item Hamilton scale score decreased by at least 50% from baseline to week 8. A remitter was defined as a patient whose Hamilton scale score was 7 or less at week 8. ^Differences between remirring/nonremirring responders and nonresponders and between remitting responders and nonresponders/nonremitting responders were not significant !p=0.51-0.98; two-way ANOVA, df=l, 3521. differences between remitting responders and nonresponders were not significant (p=0.60-1.00; two-way ANOVA. df=l, 298). Change is equal to the baseline value subtracted from the endpoint value. Thus, negative values imply improvement. trations are related to clinical response, for several reasons. From a clinical perspective, it is important to know whether plasma concentrations can be used to guide treatment in patients who fail to respond to usual doses of fluoxetine, in particular, whether plasma concentrations can be used to differentiate patients who will not respond to fluoxetine treatment from those who at usual doses are inadequately treated. From the perspective of safety, determination of a threshold plasma fluoxetine concentration required for response could potentially identify the lowest effective dose that preserves efficacy but minimizes side effects. A number of previous studies have examined the relationship between plasma fluoxetine concentrations and therapeutic outcome. Many studies have demonstrated no relationship between plasma fluoxetine concentrations and response (15-17), although other studies have suggested a curvilinear relationship between clinical response and plasma concentrations (19) (20) (21) 29) , with decreased response at higher plasma concentrations. Many of these studies, however, were limited by sample sizes that may have been inadequate to detect an effect (particularly curvilinear relationships). As a result, the relationship between plasma fluoxetine concentrations and clinical response remained uncertain.
The current study, which included more than 600 patients, differs from previous studies in having much greater statistical power. With the exclusion of nonremitting responders, there were 523 subjects in the study, which provides a 99.5% power to detect a difference as small as 20 ng/ml at a two-sided 5% concentration of significance. Thus, any effect, which in fact exists but was not detected in this study, is likely to have been small and of questionable clinical significance.
Several factors potentially limit the interpretation of these data. This study used a single, fixed dose of 20 mg/day and studied patients after 8 weeks of treatment. This dose has been found in some (although not all) studies to be as efficacious as higher doses (10-13), which suggests that if there is a therapeutic window with respect to dose concentration, most patients treated with 20 mg/day of fluoxetine fall within it. It is possible that treatment with a higher dose (which produced higher plasma concentrations in patients) would have shown a relationship between plasma concentration and response or that a lower dose would have shown a threshold effect. Similarly, it is possible that in patients treated longer than 8 weeks, plasma concentrations may be associated with factors such as relapse. Although poor patient compliance with treatment a Two patients had the same plasma concentration of 119 ng/ml.
could have reduced the observed plasma concentrations, this seems unlikely, since daily dosing records were maintained and pill counts were performed at each clinic visit.
Finding a curvilinear relationship between plasma concentrations and clinical response depends on choosing an appropriate statistical model to fit the data. We believe that the models examined are possible fits of the most likely meaningful relationships. However, we cannot rule out the possibility that employing further statistical models could demonstrate a relationship between plasma concentrations and response, although this seems unlikely. In this regard, the raw data are available on file for interested readers from Dr. Beasley, Lilly Research Laboratories, Indianapolis, Ind.
It is of interest that there is a great deal of interindividual variability in plasma concentrations in response to a uniform dose. Many factors influence observed plasma drug concentrations, including variations in absorption, distribution, and metabolic clearance rates that are influenced by genetic and other differences among individuals. A broad range of plasma concentrations in response to a given dose is thus not unexpected and is in accord with the degree of variability reported for tricyclic antidepressants. Steady state imipramine concentrations in response to a fixed dose, for example, have been reported to vary as much as 20-fold among individuals (30) .
The proportion of patients with a placebo response pattern (41%) is higher than the 20%-30% placebo response rates typically reported in older controlled trials, and it could potentially have affected the results. We believe this is unlikely, since the study was sufficiently large that even after exclusion of the placebo pattern responders, more than 300 subjects remained, preserving considerable statistical power. We also note that describing a placebo response pattern is a retrospective attempt to control for those patients who were responding to factors other than the pharmacologic effects of tluoxetine per se and may inaccurately estimate the true number of placebo responders. If, however, the true placebo response rate was in fact 41 %, it is of considerable interest, since the entry criteria and study conditions for this study followed well-established and tested procedures used over the years in clinical trials. Thus, while these results may be anomalous, they may also reflect broader changes in the population of patients who seek medical attention for depression, perhaps because of the increased awareness of depression or the availability and acceptance of antidepressant treatment. Broader changes in the population is a consideration of importance, since increased placebo response rates in clinical trials could potentially make it more difficult for active agents to demonstrate efficacy. 
